Laser Aesthetic Devices for the Management of Female Stress Urinary Incontinence

Stress urinary incontinence (SUI), defined as involuntary urine leakage during coughing, walking or weight-bearing, severely impairs women’s physical activity, mental health and quality of life. Traditional interventions including pelvic floor training, midurethral sling surgery and hormone replacement therapy carry obvious limitations such as long recovery, surgical risks or weak curative effects for mild-to-moderate cases. Minimally invasive laser aesthetic instruments represented by fractional CO₂ laser and 2940 nm Er:YAG laser have emerged as mainstream outpatient treatments for female SUI over the past decade. This paper systematically elaborates the biological mechanism, clinical efficacy, safety profile and clinical application specifications of intravaginal laser therapy, and discusses existing controversies and future optimization directions of laser devices in urogynecological practice.

1. Introduction
   SUI originates from weakened pelvic floor connective tissues, urethral sphincter atrophy and vaginal wall laxity caused by vaginal delivery, estrogen decline after menopause and aging. Globally, 30%–45% of adult women suffer varying degrees of SUI, yet over 60% of patients refuse surgical repair due to fear of incision, anesthesia and postoperative complications. Non-surgical conservative treatments like Kegel exercise demand long-term adherence and yield unsatisfactory outcomes for moderate SUI. Laser aesthetic equipment delivers controlled thermal stimulation to vaginal and periurethral tissues via minimally invasive transvaginal probes, triggering collagen remodeling without surgical trauma, which fills the treatment gap between conservative care and invasive operations.
2. Therapeutic Mechanism of Laser Devices for SUI
   Two core laser systems dominate clinical practice: microablative fractional CO₂ laser and non-ablative Er:YAG laser. Both rely on selective photothermolysis targeting tissue water molecules to generate localized controlled heating at 40–45°C, with distinct tissue penetration depths.
   First, immediate collagen contraction: thermal energy denatures loose type I and III collagen fibers in the anterior vaginal wall adjacent to the urethra, tightening supportive soft tissues and elevating urethral closure pressure instantly. Second, delayed neocollagenesis: controlled mild thermal injury activates fibroblasts, upregulates transforming growth factor-β and stimulates sustained new collagen and elastic fiber synthesis within 1–3 months post-treatment. Third, mucosal microcirculation reconstruction: laser irradiation promotes angiogenesis in atrophic vaginal epithelium, alleviating genitourinary atrophy and reinforcing urethral mucosal sealing function against urine leakage. Er:YAG laser features shallower, more uniform thermal distribution with minimal epidermal ablation, suitable for sensitive menopausal patients; fractional CO₂ laser achieves deeper penetration for severe vaginal laxity combined with SUI.
3. Clinical Efficacy and Treatment Protocol
   Current randomized sham-controlled trials focus on mild-to-moderate SUI patients. Standard regimens include 3 laser sessions at 4-week intervals, with each treatment lasting 10–15 minutes under topical vaginal anesthesia. Primary evaluation indicators cover the 1-hour pad weight test and ICIQ-UI SF incontinence questionnaire. A 2025 multicenter trial reported a 62.7% complete cure rate in the Er:YAG laser group at 6-month follow-up, versus only 18.2% in the sham group (P<0.001), with significant reductions in urine leakage frequency and improved pelvic floor function scores . Meta-analysis data further confirm that laser therapy simultaneously improves female sexual function measured by FSFI scales, bringing dual benefits for SUI and vaginal atrophy symptoms. Treatment durability lasts 12–18 months for most patients, and maintenance laser sessions every 12 months can sustain therapeutic effects.
4. Safety, Adverse Reactions and Contraindications
   Laser vaginal treatment boasts a favorable safety profile with only transient mild adverse events classified as Clavien-Dindo Grade I. Common short-term reactions include vaginal dryness, slight burning sensation and spotting, all resolving spontaneously within 3–7 days without medical intervention. Severe complications such as vaginal scarring, urethral injury or persistent pain rarely occur when operators strictly standardize laser energy parameters and probe operation routes . Absolute contraindications comprise active vaginal infection, pelvic organ malignancy, pregnancy, severe urethral stricture and uncontrolled overactive bladder. Relative contraindications include unhealed perineal wounds and autoimmune connective tissue disorders.
5. Clinical Controversies and Conclusion
   Debates remain regarding laser therapy’s long-term efficacy for severe SUI: several low-bias Cochrane reviews note that high-quality sham-controlled trials display inconsistent curative effects beyond one year, reminding clinicians that laser instruments are prioritized for mild and moderate SUI rather than a replacement for sling surgery in severe cases . Overall, laser aesthetic devices provide a painless, minimally invasive, outpatient-accessible alternative for women unwilling to receive surgery. With continuous optimization of laser wavelength, energy modulation and intelligent tissue monitoring probes, personalized laser protocols will further improve long-term therapeutic stability, making laser urogynecology a vital branch of minimally invasive aesthetic and reconstructive gynecology.